Data transparency initiatives 'could deter industry investment'
This article was originally published in SRA
The pharmaceutical industry fears that early disclosure of clinical data could impede sponsor efforts to secure patents, driving away potential investors in the process. But regulators say investors should welcome the initiatives because they will bring greater efficiency to drug development. Sue Sutter reports on the debate from the US Biotechnology Industry Organization's annual convention in Philadelphia.
Register for our free email digests: